Quick Answer
Voyager Therapeutics, Inc. reported Total Revenue of $40.37 million for fiscal year 2025.
Voyager Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $40.37M -49.5% |
$80.00M -68.0% |
$250.01M +511.2% |
$40.91M +9.3% |
$37.41M -78.1% |
$171.13M +63.9% |
| Revenue (ASC 606) | $40.37M -49.5% |
$80.00M -68.0% |
$250.01M +511.2% |
$40.91M +9.3% |
$37.41M -78.1% |
$171.13M +63.9% |
| Net Income | -$119.72M -84.2% |
-$65.00M -149.1% |
$132.33M +385.1% |
-$46.41M +34.8% |
-$71.20M -293.8% |
$36.74M +184.3% |
| Diluted EPS | -$2.04 -80.5% |
-$1.13 -138.0% |
$2.97 +345.5% |
-$1.21 +36.0% |
-$1.89 -292.9% |
$0.98 +181.0% |
| Total Assets | $252.28M -35.8% |
$393.05M +11.9% |
$351.28M +120.4% |
$159.36M -17.8% |
$193.85M -25.9% |
$261.58M -26.3% |
| Cash and Equivalents | $65.30M -8.5% |
$71.37M +3.7% |
$68.80M -30.5% |
$98.96M -15.7% |
$117.43M +12.4% |
$104.44M +21.4% |
| Stockholders Equity | $196.08M -34.6% |
$299.76M +26.8% |
$236.32M +300.4% |
$59.02M -37.9% |
$95.06M -38.4% |
$154.32M +55.1% |
| R&D Expense | $134.67M +5.7% |
$127.37M +38.2% |
$92.17M +51.7% |
$60.76M -17.6% |
$73.79M -32.2% |
$108.75M -9.2% |
| Operating Income | -$131.84M -58.3% |
-$83.29M -168.3% |
$122.01M +340.0% |
-$50.84M +30.9% |
-$73.62M -368.8% |
$27.38M +153.0% |
| Shares Outstanding | 59.05M +7.9% |
54.73M +24.3% |
44.04M +14.0% |
38.61M +1.8% |
37.92M +1.5% |
37.37M +1.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.37M | -45.7% | +157.0% |
| Revenue (ASC 606) | September 30, 2025 | $13.37M | -45.7% | +157.0% |
| Net Income | September 30, 2025 | -$27.89M | -208.4% | +16.4% |
| Diluted EPS | September 30, 2025 | -$0.47 | -193.7% | +17.5% |
| Total Assets | September 30, 2025 | $288.31M | -32.3% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $45.12M | -59.9% | +2.7% |
| Stockholders Equity | September 30, 2025 | $219.82M | -33.4% | -9.9% |
| R&D Expense | September 30, 2025 | $35.87M | +18.6% | +14.5% |
| Operating Income | September 30, 2025 | -$30.59M | -122.0% | +16.5% |
| Shares Outstanding | September 30, 2025 | 55.48M | +1.7% | +0.1% |
- Voyager Therapeutics, Inc. reported Total Revenue of $40.37 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -49.5% in Total Revenue compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Revenue (ASC 606) of $40.37 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -49.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Net Income of -$119.72 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -84.2% in Net Income compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Diluted EPS of $2.04 per share (loss) for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -80.5% in Diluted EPS compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Total Assets of $252.28 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -35.8% in Total Assets compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Cash and Equivalents of $65.30 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -8.5% in Cash and Equivalents compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Stockholders Equity of $196.08 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -34.6% in Stockholders Equity compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported R&D Expense of $134.67 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed an increase of +5.7% in R&D Expense compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Operating Income of -$131.84 million for fiscal year 2025.
- Voyager Therapeutics, Inc. showed a decrease of -58.3% in Operating Income compared to the prior fiscal year.
- Voyager Therapeutics, Inc. reported Shares Outstanding of 59.05 million shares for fiscal year 2025.
- Voyager Therapeutics, Inc. showed an increase of +7.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: